Eiger BioPharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Eiger Biopharmaceuticals

05/08/2021 22:12

* Eiger BioPharmaceuticals Inc  EIGR.OQ  reported a quarterly
adjusted loss of 57 cents​​ per share for the quarter ended in
June. The mean expectation of six analysts for the quarter was
for a loss of 55 cents per share.
* Revenue was $2.10 million​;  analysts expected $2.15 million. 
* Eiger BioPharmaceuticals Inc's reported EPS for the quarter
was a loss of 57 cents​.
* The mean earnings estimate of analysts had fallen by
about 9.5% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Eiger BioPharmaceuticals Inc shares had fallen by 11.0% this
quarter and lost 38.3% so far this year.
* The company reported a quarterly loss of $19.71 million.
* Wall Street's median 12-month price target for Eiger
BioPharmaceuticals Inc is $27.00 
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
This summary was machine generated August 5 at 09:12 p.m.  ​All
figures in US dollars unless otherwise stated